BACKGROUND Vocal fold scar and sulcus are refractory disorders characterized by fibrotic changes of the vocal folds that result in persistent dysphonia. Currently, no established pharmacological treatment exists. Hepatocyte growth factor (HGF) has demonstrated antifibrotic and regenerative effects in preclinical and early-phase clinical studies and is a promising therapeutic candidate for vocal fold fibrosis. OBJECTIVE The aim of this study is to evaluate the efficacy and safety of KP-100LI, an intracordal formulation containing a recombinant human 5-amino-acid-deleted hepatocyte growth factor (dHGF) as the active pharmaceutical ingredient for improving voice function in patients with vocal fold scar and sulcus. METHODS This is a phase III, multicenter, randomized, placebo-controlled, double-blind, parallel-group confirmatory trial conducted at eight hospitals in Japan (protocol version 4.0, 21 July 2026). The study consists of a screening period, treatment period, and 24-week observation period in the double-blind phase, followed by a continuation phase in which eligible participants receive KP-100LI. A total of 62 participants aged 18–75 years with bilateral vocal fold scar and sulcus, and a Voice Handicap Index-10 (VHI-10) score of ≥11 at both screening assessments will be enrolled. Eligible participants will be randomly assigned to receive either KP-100LI or placebo. KP-100LI will be administered by bilateral intracordal injection at a total dose of 20 μg (10 μg per vocal fold) once weekly for four consecutive weeks. Participants will be followed for 24 weeks after completion of treatment in the double-blind phase. RESULTS The primary endpoint is the proportion of participants achieving an improvement of ≥5 points in the VHI-10 score at Week 24 compared with baseline. Secondary endpoints include the proportion of participants achieving an improvement of ≥5 points in the VHI-10 score at Weeks 4, 8, and 12; changes in VHI-10 scores, normalized mucosal wave amplitude (NMWA), and Grade, Roughness, Breathiness, Asthenia, and Strain (GRBAS) scale scores from baseline to Weeks 4, 8, 12, and 24 during the double-blind phase. In addition, during the continuation phase, the proportion of participants achieving an improvement of ≥5 points in the VHI-10 score and changes in VHI-10 scores, NMWA, and GRBAS scores at Weeks 4, 8, 12, and 24 of the continuation observation period will be evaluated relative to baseline at Week 0 and baseline at Week 27. Safety assessments include adverse events and other clinical safety evaluations throughout the study. CONCLUSIONS This trial is designed to determine whether intracordal administration of KP-100LI improves voice-related outcomes in patients with vocal fold scar and sulcus. The results will provide important evidence regarding the efficacy and safety of dHGF-based regenerative therapy for these refractory vocal fold disorders. CLINICALTRIAL ClinicalTrials.gov NCT05627648; https://clinicaltrials.gov/study/NCT05627648?term=KP-100LI&rank=1 the Japan Registry of Clinical Trials jRCT2051220132; https://jrct.mhlw.go.jp/latest-detail/jRCT2051220132